IL-2 expansion of T and NK cells from growth factor-mobilized peripheral blood stem cell products: monocyte inhibition

J Immunother. 1998 Nov;21(6):409-17. doi: 10.1097/00002371-199811000-00002.

Abstract

The expansion of T and natural killer (NK) cells in growth factor-mobilized peripheral blood stem cell (PSC) products with interleukin-2 (IL-2) requires a reduction in monocyte frequency. Monocytes are enriched with stem cells during apheresis and, in this series of growth factor-mobilized PSC products from breast cancer patients, represented 36 +/- 6% of the cells in the product. Immunophenotyping studies revealed that monocytes inhibited the proliferation of NK cells (CD56+ and CD3- CD8+ CD56+ cells) and T cells (CD3+, CD4+, and CD8+ cells) during IL-2 co-culture for 7, 14, or 21 days. A reduction in monocytes resulted in 61-fold expansion of CD3- CD8+ CD56+ cells compared with a 3.7-fold increase of CD3+ cells by day 21. In addition, following IL-2 co-culture, cells from PSC products with a reduced frequency of monocytes had a significantly increased T cell mitogenic response and NK cell activity in PSC products compared with intact products. We suggest that monocytes inhibit the IL-2-dependent proliferation and augmented function of NK and T cells from growth factor-mobilized PSC products.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • CD4-Positive T-Lymphocytes / drug effects*
  • CD8-Positive T-Lymphocytes / drug effects*
  • Cell Division / drug effects
  • Drug Evaluation, Preclinical
  • Female
  • Hematopoietic Stem Cell Mobilization*
  • Humans
  • Immunophenotyping
  • Interleukin-2 / pharmacology*
  • Killer Cells, Natural / drug effects*
  • Monocytes / drug effects*

Substances

  • Interleukin-2